1.. Introduction {#s1}
================

One of the most interesting findings revealed by the Human Genome Project is that the human genome contains only 20 000--25 000 protein-coding genes.^[@DSP022C1]^ This number is unexpectedly too small. To explain this unexpected result and to understand functions of genes, it is necessary to analyze mRNA diversity.

Biologically, multiple transcripts can be generated from a single gene by alternative splicing (AS). According to several reports on genome research, AS occurs in 30--60% of human genes.^[@DSP022C2]--[@DSP022C5]^ It has been reported that AS of a single gene could produce transcripts coding for multiple proteins, each exhibiting different biochemical properties including binding, intracellular localization and regulation of enzymatic activities.^[@DSP022C6]^ AS is also of interest to the pharmaceutical research because unwanted AS of genes could lead to various genetic diseases and cancers.^[@DSP022C7]^ We have particularly focused on the analysis of AS patterns that are produce by utilizing alternative transcription start sites (TSSs). Indeed, multiple transcripts were produced from a gene by utilizing variable TSSs.^[@DSP022C8],[@DSP022C9]^ For example, the *Pcdh* gene, which contained variable TSSs, was shown to produce different transcripts;^[@DSP022C10]^ similarly, UGTs (UDP-glucuronosyltransferases), which contained more than 10 TSSs.^[@DSP022C11]^ From these findings, it is clear that to elucidate gene function, we have to further our knowledge on and understanding of all transcripts made from each gene, particularly those of the protein-coding transcripts. However, identification of all protein-coding transcripts have so far been difficult due to the fact that a large number of EST data accumulated in the databases are 3\'-EST data, which were obtained by sequencing cDNAs from the polyA-end. Thus, even though sequences of a large number of mRNAs are already known, our understanding of these mRNAs remained incomplete because of the fragmentary nature and 3′-end bias of their sequences. Because of the lack of sequence information, it has been difficult to predict TSSs and to identify all the open reading frame (ORF) regions. Although the use of next generation sequencer helped in making advances in analyzing TSSs, it still remains extremely difficult to evaluate diversities of mRNAs transcribed by each gene because of their accumulation of short-length sequences (less than 50 bases) of cDNA clones.^[@DSP022C12],[@DSP022C13]^

We sequenced ∼55 000 human full-length cDNAs, including 11 769 newly identified cDNAs described in this paper, and also obtained ∼1.45 million 5\'-end-one-pass sequences (5\'-EST).^[@DSP022C14]--[@DSP022C17]^ We believe that these cDNA sequences are very useful in analyzing the diversity of protein-coding transcripts and would definitely contribute to our understanding of mRNA. First, our cDNA clones were isolated from full-length human cDNA libraries constructed by an optimized oligo-capping method, and therefore by utilizing their sequence information, we were able to identify the TSS with 90% or better accuracy.^[@DSP022C14],[@DSP022C18]--[@DSP022C20]^ Thus, we could easily and accurately identify TSSs of even low-expressing genes, for which up until now it required comparison of a large amount of data.^[@DSP022C17]^ Second, our 5′-EST data contained, on the average, sequence information of ∼500 bases/cDNA clone, which covered two or more exons. Since the average length of the 5\'-untranslated region is believed to be 125 bases,^[@DSP022C21]^ it was possible to predict ORF regions using our 5\'-EST data. Finally, the most important point is that all of our resources were obtained from the full-length cDNAs, including the TSS and the polyA site. Moreover, we could obtain various findings on protein expression from our full-length cDNAs.^[@DSP022C16]^ These findings could not be obtained from sequences of short mRNA fragments. Since AS of genes could potentially create a large number of protein-coding transcripts, analyzing full-length cDNAs might be immensely valuable in understanding gene function.

Here, we report on our analysis of 11 769 full-length cDNAs, which were identified from our full-length cDNA libraries, and contained ORFs as a result of AS. We also present our analysis on the splice patterns and expression profiles of the identified cDNAs to explore the correlation between the mRNA diversity and gene function. Furthermore, we describe 261 full-length cDNAs with unique TSSs known as multiple variable first exon (FEV) and report on their expression profiles. Finally, we report establishing the FLJ Human cDNA Database based on the results of our analysis of the variable protein-coding transcripts generated from each gene by AS.

2.. Materials and methods {#s2}
=========================

2.1.. Construction of full-length cDNA libraries {#s2a}
------------------------------------------------

Most total RNAs isolated from various tissues and cells were purchased from Clontech and Ambion. Cells were cultured following established protocol, and cytoplasmic total RNAs were extracted from these cultured cells following a standard RNA purification method. The list of total RNAs used in this study was shown in [Supplementary Table S1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1). We constructed cDNA libraries from total RNAs by an optimized oligo-capping method (detailed method for the optimized oligo-capping is provided in the [Supplementary Method 1](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)).^[@DSP022C18],[@DSP022C19]^ Briefly, total RNAs were treated with bacteria alkaline phosphatase (TaKaRa) and tobacco acid pyrophosphatase. After that, total RNAs were ligated to the oligo-RNA using the RNA ligase (TaKaRa). Oligo-capped polyA(+) RNAs were then isolated oligo-dT columns. The first-strand cDNAs were synthesized using the Superscript II reverse transcriptase (Invitrogen), the synthesized cDNAs were amplified using the Gene Amp XL PCR kit (ABI) and the amplified product was digested with the restriction enzyme SfiI. Fragments longer than 2 kb were selected and purified by agarose gel electrophoresis and cloned into the DraIII-digested pME18SFL3 vector following the standard methods. The 5′-end-one-pass sequences of cloned cDNAs were analyzed using the ABI 377 and 3700 sequencers (ABI). The 5\'-end fullness rate of the constructed oligo-capped cDNA libraries was evaluated as described previously,^[@DSP022C22],[@DSP022C23]^ and the detailed method for determining the 5\'-end fullness rate is provided in the [Supplementary Method 2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1).

2.2.. Genome mapping and clustering {#s2b}
-----------------------------------

The 5′- and 3′-ends of cDNA sequences and the full-length cDNA sequences ([Supplementary Table S2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)) were mapped onto the human genome (UCSC hg 18 NCBI Build 36.1). Possible local alignments between the cDNAs and genome sequences were identified by using the NCBI Mega BLAST program (ftp://ftp.ncbi.nih.gov/blast/). For each cDNA, best mapping of the sequence was determined from these local alignments using a dynamic programming technique that optimized the identity, coverage and topology of exons. The joining portions of consecutive local alignments were refined so as to restore the consensus sequence in the canonical splice sites. On the basis of the mapping results clustering of cDNA sequences were performed as follows: two cDNA sequences were grouped into the same cluster if their mapped positions shared at least one base on the genome. In general, each cluster corresponded to a single gene locus.

2.3.. Identification of alternatively spliced variants of mRNAs {#s2c}
---------------------------------------------------------------

On the basis of the results of genome mapping and clustering analysis, ESTs that had different regions compared with known full-length cDNAs by AS were selected by Intris, a viewer for cDNA-genome alignments used for analysis of splicing variants and expression profiles.^[@DSP022C24]^ To exclude the cDNA fragments derived from the immature mRNA and genomic DNA, reliability of mRNA was evaluated by using not only the human EST data but also the data conserved from other animals (Phastcons; obtained from UCSC Genome Browser). We predicted the ORF regions from the 5\'-end sequences of full-length cDNAs on selected ESTs by using ATGpr (<http://flj.lifesciencedb.jp/top/>).^[@DSP022C25]^ Next, we excluded those ESTs from the selected analytical targets when the predicted ORF regions of the selected ESTs were the same as the ORF regions of known full-length cDNAs. In addition, even if the predicted ORF regions were different from the ORF regions of known full-length cDNAs, we excluded cDNA clones containing extremely short ORF regions (mostly 60 amino acids or less) compared with the other full-length cDNAs that mapped in the same locus of the human genome. The selected cDNAs were further sequenced by primer walking method using an ABI3700 sequencer (ABI) to obtain information on 500 additional bases, and the ORF regions were predicted again by using the ATGpr.^[@DSP022C25]^ We also evaluated the predicted ORF regions by using TRis,^[@DSP022C26]^ translated region inspector, and examined their novelty of amino acid sequences by using ALVISION,^[@DSP022C27]^ aligns two cDNA sequences that are splicing variants allowing large gaps. When the reliability of the predicted ORF region was insufficient, we excluded it from our list of analytical targets. When the predicted ORF regions of the selected cDNAs were judged reliable and different from those of the known full-length cDNAs, we then sequenced the full-length cDNA clone all the way up to the stop codon. Consequently, we completely sequenced 11 769 of full-length FLJ cDNAs and analyzed their tissue-specific expression. A detailed method for the analysis of the tissue-specific expression of the cDNAs is provided in the [Supplementary Method 3](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1). We have also constructed the FLJ Human cDNA Database (<http://flj.lifesciencedb.jp>) that contained these sequence information. A detailed method for the analysis of AS by using the information available in the FLJ Human cDNA Database is provided in the [Supplementary Method 4](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1). Sequences of 11 769 of our full-length cDNAs were also deposited in the DDBJ/GenBank/EMBL databases (AK293122--AK304890).

2.4.. Functional analysis of full-length cDNAs *in silico* {#s2d}
----------------------------------------------------------

Sequences of cDNAs were analyzed for the signal sequences, trans-membrane domains and motifs in the encoded proteins by using Signal P ver. 3.0 (<http://www.cbs.dtu.dk/services/SignalP/>), SOSUI ver. 1.5 (Mitsui Knowledge Industry) and Pfam 19.0 (November 2005; <http://pfam.sanger.ac.uk/>), respectively. We obtained information on motifs showing E-values of e-30 or more from the Pfam analysis, and based on these results, we then categorized each cDNA and the corresponding gene according to its gene ontology (GO) (<http://www.geneontology.org/>) classification by using InterPro (<http://www.ebi.ac.uk/interpro/>).

2.5.. Quantitative real-time PCR analysis {#s2e}
-----------------------------------------

Total RNAs derived from various tissues were purchased from Clontech, Ambion and STRATAGENE (listed in [Supplementary Table S4](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). From 10 µg of each total RNA, first-strand cDNAs were synthesized using random primers and the Superscript III reverse transcriptase (Invitrogen) following the manufacturer\'s instructions. Real-time PCR was performed using TaqMan Universal Master Mix (ABI) or SYBR Master Mix (ABI) on an ABI Fast7500 System (ABI) according to the manufacturer\'s instructions. Approximately 300 ng of template cDNAs was used in each PCR reaction. Probes and primers were designed using the Primer Express3.0 (ABI) (refer to [Supplementary Table S5](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1) for the list of primers). The expression levels of genes were normalized with respect to that of the human GAPDH, and expression values of individual genes were calculated by comparing their Ct values to that of the control using the RQ software (ABI). The expression levels of genes were represented in log~10~ base. Samples were run in duplicates and the data shown are the average of two experiments.

3.. Results and discussion {#s3}
==========================

3.1.. Identification of human genes {#s3a}
-----------------------------------

It is known that AS could produce mRNA diversity.^[@DSP022C2]--[@DSP022C6]^ However, to analyze the mRNA diversity, it is necessary to identify human genes (i.e. the genome loci from where the protein-coding mRNAs are transcribed). We obtained 1.45 million human full-length cDNAs and sequenced their 5\'-ends. We previously selected ∼30 000 cDNAs from these full-length cDNAs based on the novelty analysis, and completely sequenced them.^[@DSP022C14]--[@DSP022C16]^ Later, we also selected ∼25 000 cDNAs based on the mRNA diversity and also sequenced them completely. In our quest to identify human genes, we used, for our analysis, the sequence information on these 55 000 full-length human cDNAs including 11 769 cDNAs reported in this paper ([Supplementary Table S2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Furthermore, for the analysis, we not only used our own data but also data from 52 000 full-length human cDNA sequences available from the public databases, 30 000 human RefSeq (NCBI Reference Sequences; <http://www.ncbi.nlm.nih.gov/RefSeq/>) and 48 000 Ensembl, human gene transcripts (<http://www.ensembl.org/index.html>). In addition, we used EST sequences obtained by us and from other public databases ([Supplementary Table S2](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). All the sequence data we collected were mapped onto the human genome and clustered. We then examined reliability of each full-length cDNAs by Intris^[@DSP022C24]^ using sequences of all full-length cDNAs and ESTs mapped on the same locus of the genome, and based on this analysis, we selected only the reliable cDNAs for the gene identification analysis. We determined the genome locus of each one of the selected reliable cDNA and manually checked them one by one to identify the corresponding gene. As a result, we identified 23 241 human genes from this analysis (Fig. [1](#DSP022F1){ref-type="fig"}A). Each gene cluster was classified into three categories based on the reliability scores. The number of genes in the high reliability category (high category) were 16 754. Sequences of cDNAs belonging to the high-category group were found to be already analyzed because the genome locus was covered by sequence information available from the three types of databases, the human full-length cDNAs, RefSeq and Ensembl. It accounted for 72% of the total number of genes. The number of genes with intermediate reliability (medium category) was 2854. As for the medium-category group, the genome locus was covered by sequence information available from only the human full-length cDNAs or from two out of three of the above-mentioned databases. The number of genes with low reliability (low category) were 3633. As for the low-category group, the gene locus was covered by sequence information available only from the RefSeq or the Ensembl.

![Clustering of human cDNA sequences. (A) Estimation of the number of human genes from full-length cDNAs and ESTs. Outline of our gene prediction method from the human full-length cDNAs and ESTs mapped to human genome is schematically shown. For each one of the predicted genes, classification reliability was evaluated manually. (B) Cover rate of FLJ EST sequences and (C) cover rate of FLJ full-length sequenced cDNAs. Results of reliability analysis according to the category based on the cover rates of 1.45 million of ESTs (B) and 55 000 full-length cDNAs (C).](dsp02201){#DSP022F1}

To further assess these reliabilities, we next calculated the cover rate of genes using our cDNAs. First, the cover rate was calculated using our 1.45 million FLJ ESTs, and we found a positive correlation between these reliabilities and the cover rate of FLJ ESTs (Fig. [1](#DSP022F1){ref-type="fig"}B). Next, we calculated the cover rate of genes using our 55 000 FLJ human full-length cDNA sequences. In this case, we also found a positive correlation between the reliability and the cover rate similar to that was observed for the ESTs (Fig. [1](#DSP022F1){ref-type="fig"}C). Thus, we were able to verify reliability irrespective of whether we used the sequences of our ESTs or full-length cDNAs in the analysis.

3.2.. Analysis of AS and functional classification of sequenced full-length cDNAs by GO {#s3b}
---------------------------------------------------------------------------------------

We selected 25 000 full-length cDNAs from among the identified genes by focusing our attention on AS and subsequently sequenced them. In addition, from these cDNAs, we selected 11 769 of human full-length cDNAs in which the ORF regions were predicted to be different from the known full-length cDNAs, and then classified them by GO according to their predicted functions. First, ESTs exhibiting a different splicing pattern than the known full-length cDNAs were selected and were completely sequenced. From the sequence analysis, we were able to predict the ORF regions in only 30% of them (results not shown). Interestingly, a number of cDNA, for which we were unable to predict the ORF region, were thought to produced by AS. But, because our target was to be able to predict the function of the gene from the sequence of its transcript, it was necessary to select protein-coding transcripts efficiently. It is difficult to predict the ORF region correctly from the EST sequences lacking the TSS. However, our 5\'-EST sequences not only contained the TSS but also contained sequence information on an average of 500 bases from the TSS. Therefore, we were able to correctly predict the ORF regions of our 5\'-EST by using ATGpr.^[@DSP022C25]^ As a result, the number of clones containing unpredictable ORF regions decreased to ∼10%. Moreover, by using the tools such as TRins^[@DSP022C26]^ for inspecting the translated region and ALVISION^[@DSP022C27]^ for evaluating the novelty of amino acid sequences, we succeeded in identifying the ORF regions with high accuracy. Consequently, we obtained 11 769 of human full-length cDNAs in which the ORF regions were predicted to be different from the known full-length cDNAs ([Supplementary Table S3](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Ninety-six percent of these cDNAs-encoded proteins which differed in at least 10 amino acids from those encoded by their respective known full-length cDNAs, mainly because we selected them based on their altered ORF regions as a result of AS. These full-length cDNAs covered 7025 of 23 241 genes that we had originally identified.

Once it was established that human genes could produce multiple protein-coding transcripts, it was important to analyze their putative functions. The GO classification analysis was performed for all 11 769 our full-length cDNAs using Pfam, and their predicted functions, obtained from this analysis, are summarized in Table [1](#DSP022TB1){ref-type="table"}. The classification results revealed that a large number of our cDNA clones were listed under the GO molecular function categories 'nucleotide binding', 'nucleic acid binding', 'protein binding', 'hydrolase activity', 'transferase activity' and 'oxidoreductase activity'. Because 11 769 of our full-length cDNAs had ORF regions different from those of the known full-length cDNAs, we also analyzed their functions by predicting domains and motifs using Pfam, SOSUI and SignalP ([Supplementary Table S3](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Consequently, we discovered full-length cDNAs that encoded proteins with altered functional domains and signal sequences as a result of AS.

###### 

Functional classification of the 11 769 full-length cDNAs based on the molecular function hierarchy of GO

  Functional categorization (GO: molecular function)    Number of matched cDNAs
  ----------------------------------------------------- -------------------------
  Binding                                               
   Nucleotide binding                                   681
   Nucleic acid binding                                 341
   Protein binding                                      202
   Ion binding                                          149
   Lipid binding                                        28
   Tetrapyrrole binding                                 27
   Neurotransmitter binding                             24
   Carbohydrate binding                                 22
   Other bindings                                       57
  Catalytic activity                                    
   Hydrolase activity                                   506
   Transferase activity                                 479
   Oxidoreductase activity                              207
   Ligase activity                                      85
   Lyase activity                                       47
   Helicase activity                                    38
   Isomerase activity                                   26
   Other catalytic activities                           106
  Enzyme regulator activity                             
   GTPase regulator activity                            45
   Enzyme inhibitor activity                            44
   Other enzyme regulator activities                    21
  Motor activity                                        
   Microtubule motor activity                           24
   Other motor activities                               20
  Signal transducer activity                            
   Receptor activity                                    124
   Receptor binding                                     25
   Other signal transducer activities                   40
  Structural molecule activity                          
   Structural constituent of ribosome                   25
   Other structural molecule activities                 56
  Transcription regulator activity                      
   Transcription factor activity                        138
   Other transcription regulator activities             39
  Translation regulator activity                        
   Translation factor activity, nucleic acid binding    25
  Transporter activity                                  
   Ion transporter activity                             169
   Carrier activity                                     90
   Channel or pore class transporter activity           79
   ATPase activity, coupled to movement of substances   39
   Other transporter activities                         131
  Others                                                2
  Molecular function unknown                            45

If a protein was predicted to belong to two or more categories, all categories were included for counting.

3.3.. Classification of splicing patterns of full-length cDNAs {#s3c}
--------------------------------------------------------------

Up until now, majority of the ESTs entered in the public databases were 3\'-EST. We succeeded in constructing full-length cDNA libraries efficiently by using the optimized oligo-capping method and obtained ∼1.4 million 5\'-ESTs of full-length cDNAs constructed by this method.^[@DSP022C18],[@DSP022C19]^ Our 5\'-EST sequences were especially useful for the analysis of TSSs because 90% or more of our cDNAs contained the TSSs. We analyzed the splicing patterns of the 11 769 cDNAs by using the 5\'-EST sequence data (Fig. [2](#DSP022F2){ref-type="fig"}). Results of this analysis revealed that 3403 cDNAs, which correspond to ∼30% of all cDNAs, were transcribed using alternative TSSs (Type A), and thus, the predicted proteins contained new amino acid sequences at their N-terminal ends. In addition, 1962 cDNAs in Type A (designated as Type A1) contained FEV, due to transcripts originating from a TSS that was previously ignored because it was mapped in an intron region of the genome or transcripts originating from a TSS that was mapped upstream from the one that was analyzed before. Taken together, these results led to the discovery of new exons. We analyzed expression profiles of the genes containing multiple TSSs and discovered that the same gene could code for proteins with diverse function in different tissues by the proper utilization of alternative TSS. There were 8277 cDNAs (i.e. ∼70% of all the full-length cDNAs) that were transcribed from the previously identified TSSs, but contained different ORF region because of AS; they were designated as Type B. Because we used our 5\'-EST data for the selection, a lot of Type B cDNAs were predicted to contain N-terminal sequences different from those of the known cDNAs, except for a portion of cDNAs which were either selected by PCR or found during sequencing analysis. To assess whether AS or use of alternative TSS could alter the function of the predicted protein, we compared the GO functional categories of the Type A and Type B (Table [2](#DSP022TB2){ref-type="table"}). Our results showed that majority of the Type A belonged mainly to the GO molecular function categories of 'neurotransmitter binding', 'enzyme activator activity', 'cyclase activity', 'ATPase activity, coupled to movement of substances' and 'GTPase regulator activity'. Thus, by using our 5\'-EST data, a lot of valuable information were obtained regarding the diversity of TSS and amino acid sequences at the N-terminal ends of proteins. However, since only a portion of the full-length cDNAs was selected for this analysis, information on sequence diversity in regions beyond 500 bases from the TSSs were not obtained. We believe that there are additional alternately spliced transcripts which remained to be analyzed in the future studies.

![Classifications of the 11 769 full-length cDNAs based on splicing patterns. The 11 769 human full-length cDNAs were classified according to their TSS utilization. Type A: these cDNAs were derived from transcripts which were generated utilizing a TSS different than the previously analyzed TSS of the gene. Type A1: cDNAs contained a sequence variation known as FEV. Type A2: this class of cDNAs did not have the FEV feature. Type B: these cDNAs were derived from transcripts that were generated utilizing the same TSS as the previously analyzed TSS, but were found to be alternatively spliced. We could not classify 89 cDNAs because they coded for newly identified proteins.](dsp02202){#DSP022F2}

###### 

Functional classification of two types of splicing patterns of 11 769 full-length cDNAs based on GO category analysis

  Functional categorization (GO: molecular function)    Number of matched cDNAs                 
  ----------------------------------------------------- ------------------------- ------------- ------
  Binding                                                                                       
   Lipid binding                                        4 (14.3)                  24 (85.7)     28
   Tetrapyrrole binding                                 5 (18.5)                  22 (81.5)     27
   Neurotransmitter binding                             12 (50.0)\*               12 (50.0)     24
   Carbohydrate binding                                 4 (18.2)                  18 (81.8)     22
   Cofactor binding                                     3 (16.7)                  15 (83.3)     18
   Steroid binding                                      1 (10.0)                  9 (90.0)      10
  Catalytic activity                                                                            
   Helicase activity                                    4 (10.5)                  34 (89.5)     38
   Small protein activating enzyme activity             2 (18.2)                  9 (81.8)      11
   Cyclase activity                                     6 (54.5)\*                5 (45.5)      11
  Enzyme regulator activity                                                                     
   GTPase regulator activity                            31 (68.9)\*               14 (31.1)     45
   Enzyme activator activity                            6 (50.0)\*                6 (50.0)      12
  Structural molecule activity                                                                  
   Structural constituent of ribosome                   1 (4.0)                   24 (96.0)     25
  Transporter activity                                                                          
   ATPase activity, coupled to movement of substances   23 (59.0)\*               16 (41.0)     39
   Electron transporter activity                        2 (13.3)                  13 (86.7)     15
  Total                                                 1344 (32.0)               2862 (68.0)   4206

The ratio of Type A and Type B is 3:7 as shown by total. Total is all the results of classification in the category of molecular function. If a protein was predicted to belong to two or more categories, all categories were included for counting.

\*Functional categories biased to Type A.

3.4.. Analysis of genes showing tissue-specific expression {#s3d}
----------------------------------------------------------

We analyzed expression of genes producing multiple protein-coding transcripts by AS and found that many of these transcripts were expressed in specific tissues or cells, suggesting that the genes likely use this diversity according to the need and situation. We next analyzed expression profiles of 10 069 cDNAs, which corresponded to 5542 genes, out of 11 769 full-length cDNAs we identified in this study. As our cDNA libraries were constructed using RNAs derived from more than 100 different types of tissues and cells, we therefore used the 5′-EST data for analyzing gene expression. We next analyzed gene expression profiles of Type A1 cDNAs containing the FEV diversity and found that the FEVs of 261 cDNAs, which correspond to 155 genes, showed specific expression patterns that were different from those already obtained for the genes with alternative TSSs (Table [3](#DSP022TB3){ref-type="table"}). Thus, like the genes with alternative TSSs, the expression patterns of the genes with FEVs likely depended on the tissue and condition. Consequently, we found genes producing multiple protein-coding transcripts by AS.

###### 

Expressions of a selected list of 261 FEV-containing cDNAs (155 genes)

  FLJ ID     Specific expression   Gene symbol   FLJ ID     Specific expression   Gene symbol   FLJ ID     Specific expression   Gene symbol   FLJ ID     Specific expression   Gene symbol
  ---------- --------------------- ------------- ---------- --------------------- ------------- ---------- --------------------- ------------- ---------- --------------------- -------------
  FLJ50079   Brain                 NRK           FLJ52319   Trachea               GNE           FLJ55043   FB, NT                PDZRN3        FLJ57051   Brain                 Pld5
  FLJ50162   Brain                 LARGE1        FLJ52354   Brain, NT             CHRNB1_pre    FLJ55050   Brain                 EPS15         FLJ57068   FB                    FGF13
  FLJ50199   Brain                 ARHGEF6       FLJ52356   Testis                ARMC4         FLJ55194   Brain                 Unknown       FLJ57107   Brain, NT             CHRNB1_pre
  FLJ50365   Trachea               CRISPLD1      FLJ52358   Testis                TP73          FLJ55226   FB                    CHST10        FLJ57108   Brain                 SNAP91
  FLJ50390   Brain                 GRIA1_pre     FLJ52367   Testis                IQGAP2        FLJ55256   Synovial              TFEC          FLJ57207   Im                    Unknown
  FLJ50398   Testis                IQGAP2        FLJ52368   Testis, Trachea       ARMC4         FLJ55265   Im                    Unknown       FLJ57232   Testis                PRCP_pre
  FLJ50459   Brain                 ETV1          FLJ52384   Im                    PTPN3         FLJ55281   Heart, Fetal heart    SLC5A1        FLJ57269   Brain                 BTBD10
  FLJ50460   Brain                 DLG4          FLJ52407   Testis                CRB1_pre      FLJ55284   FB, NT                MAGI2         FLJ57290   Trachea               CRISPLD1
  FLJ50484   Brain                 SLC26A4       FLJ52427   Brain                 AMPD3         FLJ55338   FB                    CLASP1        FLJ57298   Brain                 RAPGEF4
  FLJ50494   Brain                 ETV1          FLJ52435   Testis                MARCH7        FLJ55344   Brain                 DYSF          FLJ57302   Brain                 RAPGEF4
  FLJ50523   Brain                 PEX5L         FLJ52438   Brain                 RIMS1         FLJ55381   FB                    SLC44A5       FLJ57330   Brain                 APBB1
  FLJ50526   Brain                 PEX5L         FLJ52453   Testis                AMPD3         FLJ55423   Placenta              NRK           FLJ57521   Tu                    PPFIBP2
  FLJ50533   Brain                 SLC6A9        FLJ52496   Brain                 TSPAN5        FLJ55434   Testis                POMGNT1       FLJ57884   FB                    FGF13
  FLJ50539   Brain, NT             DCAMKL1       FLJ52520   FB                    EOMES         FLJ55460   Brain                 SEMA5B_pre    FLJ57888   Brain                 SGCB
  FLJ50557   Brain                 MAP7          FLJ52731   Brain                 SPRED2        FLJ55461   NT                    KLHL13        FLJ57953   Brain                 STAU
  FLJ50577   FB                    DLG4          FLJ52750   Brain                 ARHGEF7       FLJ55481   NT                    RGMA_pre      FLJ58008   Brain                 PPP2R2B
  FLJ50619   NT                    ELAVL4        FLJ52810   Testis                GABRB3_pre    FLJ55495   Testis                PCYT2         FLJ58099   Brain                 CLTCL1
  FLJ50623   Brain, NT             DCAMKL1       FLJ53109   Testis                PPP2R5E       FLJ55504   Testis                KLHL13        FLJ58366   Brain                 RIMS1
  FLJ50641   Brain                 ETV1          FLJ53114   Testis                NCAM2_pre     FLJ55514   Brain, Tu             EGFR_pre      FLJ58368   Brain                 RAPGEF4
  FLJ50646   FB                    DLG4          FLJ53167   NT                    CUL4B         FLJ55516   Tu                    LIMS1         FLJ58494   Brain                 Unknown
  FLJ50725   Testis                ATPAF1        FLJ53184   Brain                 PPFIA2        FLJ55607   Brain, Trachea        HDAC9         FLJ58753   Brain                 ARHGEF3
  FLJ50745   Testis                CCNA1         FLJ53222   FB                    MLLT3         FLJ55622   Testis                MMRN1_pre     FLJ58755   Brain                 CHN2
  FLJ50761   Brain                 LRIG1_pre     FLJ53242   Testis                CLASP1        FLJ55627   Testis                MOV10L1       FLJ58966   Im                    RAB37
  FLJ50773   Brain                 CALB1         FLJ53247   Testis                IDE           FLJ55628   Testis                LOXHD1        FLJ59303   Brain                 DOCK4
  FLJ50776   Brain                 ARHGEF6       FLJ53252   Testis                CDH2_pre      FLJ55641   Brain, NT             JARID2        FLJ59333   Tu                    RARG
  FLJ50810   FB, NT                MAGI2         FLJ53320   Brain                 DLGAP1        FLJ55662   Im                    FGR           FLJ59338   Tu                    RARG
  FLJ50844   Brain                 WARS2_pre     FLJ53324   Brain                 TJP2          FLJ55664   Testis                NTRK3_pre     FLJ59345   Brain                 PPFIA2
  FLJ50917   Testis                PCCB_pre      FLJ53330   Brain, NT             EXOC4         FLJ55778   Brain                 CLASP1        FLJ59425   Placenta              SH3KBP1
  FLJ50956   Brain                 RAPGEF4       FLJ53518   Testis                POMGNT1       FLJ55834   Brain, NT             FGF11         FLJ59496   Brain                 CHN2
  FLJ50959   Brain                 RAPGEF4       FLJ53578   Brain                 Rims1         FLJ55856   Testis                ARHGEF3       FLJ59502   Brain                 PPFIA2
  FLJ50961   Brain                 TMEM16C       FLJ53606   NT                    AKT1          FLJ55859   Testis                ST7L          FLJ59511   Brain                 GRIA1_pre
  FLJ50989   FB                    EOMES         FLJ53680   Testis                KIF2C         FLJ55865   Im                    SLC43A2       FLJ59545   Brain                 EML2
  FLJ51025   Kidney                NOX4          FLJ53829   Brain                 APBB1         FLJ55903   FB                    GPR161        FLJ59625   Brain                 ARHGEF7
  FLJ51027   Kidney                NOX4          FLJ53875   Brain                 APBB1         FLJ55905   Im                    FGD4          FLJ59641   Testis                PPFIA2
  FLJ51073   FB                    EOMES         FLJ53929   Im                    PTPN4         FLJ55906   Testis                KIFC3         FLJ59648   Im                    DYSF
  FLJ51155   Testis                Unknown       FLJ53980   Brain                 PPM1F         FLJ55918   Brain                 EML2          FLJ59678   Brain                 PEX5L
  FLJ51157   Testis                HDAC4         FLJ53990   Brain                 GABRB3_pre    FLJ55961   Brain                 GRM4_pre      FLJ59684   Brain                 PLEKHG5
  FLJ51174   Im                    HDAC4         FLJ53997   Brain                 CTNNA2        FLJ55997   Brain                 CPNE6         FLJ59710   Brain                 MCF2
  FLJ51177   Im                    HDAC4         FLJ53999   Brain                 GAB1          FLJ56033   Testis                Unknown       FLJ59717   FB                    TBR1
  FLJ51210   Brain                 KIFC3         FLJ54008   Brain                 TPCN1         FLJ56036   Tu                    KIFC3         FLJ59769   Im                    PLEKHG5
  FLJ51383   Testis                PPP2R5A       FLJ54011   Brain                 PPFIA2        FLJ56037   Testis, Prostate      CUL2          FLJ59799   Testis                CTNNA2
  FLJ51528   Im                    BTNL8_pre     FLJ54016   Testis                DIP13B        FLJ56038   Small intestine       Unknown       FLJ59802   Testis                ADCY5
  FLJ51566   Brain                 PDK1          FLJ54093   Brain                 GPHN          FLJ56044   Brain                 OXR1          FLJ59806   Im                    HDAC4
  FLJ51606   Trachea               HABP2_pre     FLJ54100   Brain                 CHN2          FLJ56093   Brain                 PTPRR_pre     FLJ60503   Brain                 LARGE1
  FLJ51663   Testis                CPS1_pre      FLJ54331   Brain, Osteoclast     Unknown       FLJ56095   Brain                 KLHL13        FLJ60665   Tu                    SLC44A5
  FLJ51675   Brain                 ETV1          FLJ54394   Testis                CRB1_pre      FLJ56110   FB                    GOLSYN        FLJ60667   Tu                    SLC44A5
  FLJ51685   Testis                MCF2          FLJ54513   Testis                WDR59         FLJ56116   FB                    APLP1         FLJ60693   FB                    PHF21B
  FLJ51695   Im                    TP74          FLJ54541   FB                    EXOC4         FLJ56136   NT                    SLC2A14       FLJ60998   Testis                INPP4B
  FLJ51706   Testis                RAPGEF4       FLJ54577   NT                    HDAC9         FLJ56137   Im                    Unknown       FLJ61124   Brain                 RAB37
  FLJ51734   Uterus                TMEM16C       FLJ54580   NT                    HDAC9         FLJ56142   NT                    AMOTL2        FLJ61133   FB                    EXOC4
  FLJ51737   Brain                 ARHGEF6       FLJ54612   Brain                 SH3KBP1       FLJ56148   Brain                 PLEKHG5       FLJ61370   FB                    SNCAIP
  FLJ51769   Testis                IQGAP2        FLJ54642   Brain                 APBB1         FLJ56167   Testis                KLHL12        FLJ61443   Testis                LARGE1
  FLJ51805   Brain                 RIMS2         FLJ54658   Brain                 LSAMP_pre     FLJ56226   NT                    SNCAIP        FLJ61560   Trachea               TJP2
  FLJ51859   Brain                 APBB1         FLJ54672   Brain                 DOCK4         FLJ56370   Testis, Prostate      FKBP8         FLJ61674   Brain                 PEX5L
  FLJ51873   Brain, NT             AGPS_pre      FLJ54673   Brain                 Unknown       FLJ56376   Brain                 MTMR1         FLJ61679   Brain                 APBB1
  FLJ51910   FB                    GTPBP3        FLJ54674   Brain                 TPCN1         FLJ56411   Brain                 GRIA2_pre     FLJ53199   Brain ↓               NEDD4L
  FLJ51934   Im                    AOAH_pre      FLJ54690   Brain                 BACE1_pre     FLJ56420   Testis                DNPEP         FLJ59993   Brain ↓               RIMS1
  FLJ51957   NT                    ELAVL4        FLJ54693   Brain                 BACE1_pre     FLJ56452   Brain                 EML2          FLJ55591   Brain ↓               ARHGEF3
  FLJ51977   Brain                 Unknown       FLJ54702   Brain                 DLGAP1        FLJ56634   Brain                 GRM4_pre      FLJ56152   Brain ↓               ARHGEF7
  FLJ52027   Testis                ATPAF1        FLJ54724   FB                    DLG2          FLJ56895   Testis                EML2          FLJ58411   FB ↓                  CACNB3
  FLJ52034   Im                    Unknown       FLJ54738   Brain                 PDZRN3        FLJ56912   Uterus                FBLN2_pre     FLJ58949   FB ↓                  CACNB3
  FLJ52037   Im                    GRAP2         FLJ54742   Testis                Slmap         FLJ56913   Placenta, Uterus      FBLN2         FLJ57810   Tu ↓                  A2ML1
  FLJ52039   Im                    GRAP2         FLJ54746   NT                    PDZRN3        FLJ56957   Brain                 TMEM16C       FLJ53545   Tu ↓                  RARG
  FLJ52041   Im                    Unknown       FLJ54751   NT                    SUV420H1      FLJ56961   Brain                 CLTCL1                                         
  FLJ52042   Im                    GRAP2         FLJ54906   Trachea               TMC5          FLJ56973   Brain                 TMEM16C                                        
  FLJ52288   Testis                ARMC4         FLJ54987   FB                    PHF21B        FLJ56979   Brain                 MYRIP                                          

We analyzed expression profiles of the first exons of ∼1.5 million 5\'-ESTs constructed by the oligo-capping method. From this analysis, we selected 261 full-length cDNAs based on the expression levels of their FEVs in specific tissues. Expression levels of cDNAs indicated without any label and with a '↓' label were high and low, respectively, in the respective tissues.

\*NT: NT2 cell induced by retinoic acid; FB, fetal brain; Im, immune tissues; Tu, tumor tissues; pre, precursor; unknown, function unknown.

3.5.. Analysis of expression patterns of tissue-specific expressed genes {#s3e}
------------------------------------------------------------------------

We quantified tissue-specific expressions of 13 out of 261 selected cDNAs by real-time PCR (Fig. [3](#DSP022F3){ref-type="fig"}). Results of our analysis especially suggested that there was a strong relationship between the tissue-specific expression and diversity of gene function or disease. We compared the expression profile of a specific gene by utilizing the TSS identified in this study with that of the same gene in which a previously identified TSS was utilized for expression. These results are summarized in [Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1) and are discussed below in more detail.

![Quantitative evaluation of selected genes by real-time PCR. Expression levels of the first exon regions of the selected genes were analyzed by real-time PCR. The data were normalized with respect to that of the human GAPDH as described in the Materials and methods section. The expression levels of genes were represented in log~10~ base. Expression levels of cDNAs labeled '\$\$' represent the very low expression level or undetected. (A) FGF13, (B) OXR1, (C) C6orf142, (D) PLD5, (E) FGD4, (F) C6orf32. BW, brain, whole; BC, brain, cerebellum; BF, fetal brain; SP, spleen; BM, bone marrow; TH, thymus; OV, ovary; PR, prostate; UT, uterus; MT, mixture of tumor human tissues; MN, control, mixture of normal human tissues; KT, kidney tumor; LT, lung tumor.](dsp02203){#DSP022F3}

First example, FGF13 is a gene that belongs to the FGF family and is believed to play roles in cell proliferation and differentiation, and also in neuronal differentiation.^[@DSP022C28],[@DSP022C29]^ FLJ57884 and FLJ57068 cDNAs exhibited different ORF regions as a result of FEV and were splicing variants of the known FGF13 cDNA. The TSSs we found in each one of them were located upstream from the TSS of FGF13. Whereas the known TSS of FGF13 was expressed highly in both fetal and adult brains, the TSSs of both FLJ57884 and FLJ57068 cDNAs were highly expressed only in the fetal brain. Moreover, the TSS of our FLJ57068 cDNA was also expressed highly in the kidney cancer (Fig. [3](#DSP022F3){ref-type="fig"}A). Second example, OXR1 is one of the oxidation stress receptivity genes localized in mitochondria.^[@DSP022C30]^ The TSS of known OXR1 was expressed at equal levels in various tissues. But the TSS we identified in the FLJ56044 cDNA was located upstream from the known TSS of OXR1 and was highly expressed in brain, kidney cancer and lung cancer (Fig. [3](#DSP022F3){ref-type="fig"}B). Thus, these results suggested that these two genes were using different TSSs to regulate their expression levels in the brain. Moreover, our results also suggest that, for both genes, only one of the TSSs was preferentially recognized by the transcription machinery in the cancerous tissue.

Third example, C6orf142 (chromosome 6 ORF 142) is a gene of an unknown function. The known TSS of C6orf142 was highly expressed in the heart. However, the TSS we identified in the FLJ58494 cDNA, which was located downstream from the previously identified TSS of C6orf142, was highly expressed in both fetal and adult brains (Fig. [3](#DSP022F3){ref-type="fig"}C). Fourth example, PLD5 is one of the phospholipid-splitting enzymes presumably involved in the intracellular signaling.^[@DSP022C31]^ Although the known TSS of PLD5 was expressed equally in various tissues, the TSS we identified in the FLJ57051 cDNA, which was located downstream of the previously identified TSS of PLD5, was highly expressed in the brain (Fig. [3](#DSP022F3){ref-type="fig"}D). Fifth example, SPRED2 is a Ras inhibitory factor belonging to the Sprouty/Spred family.^[@DSP022C32]^ The TSS we identified in the FLJ52731 cDNA, which was located downstream from the known TSS of SPRED2, was expressed highly in the brain ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Sixth example, SEMA5B is a nerve guidance factor which is involved in organogenesis, angiogenesis and oncogenesis.^[@DSP022C33]^ The TSS we identified in the FLJ55460 cDNA, which was located downstream from the known TSS of SEMA5B, also was expressed highly in the brain ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Seventh example, CACNB3 is a calcium channel beta-3 subunit, which is involved in modifying sympathetic nervous system, olfaction and control of blood pressure.^[@DSP022C34]^ Although the known TSS of CACNB3 was expressed highly in both fetal and adult brains, the newly identified TSSs of FLJ58949 and FLJ58411 cDNAs, both of which were located downstream from the known TSS of CACNB3, were expressed at a low level in the brain ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). These cDNAs exhibited different ORF regions as a result of AS. Eighth example, BACE1 is a peptide hydrolase that cleaves the amyloid precursor protein and is one of the factors involved in Alzheimer\'s disease.^[@DSP022C35]^ The known TSS of BACE1 was expressed equally in various tissues. However, the TSS we identified in the FLJ54690 cDNA, which was located downstream from the known TSS of BACE1, was expressed highly in the brain ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Thus, these six genes regulated their expression levels in the brain using a specific TSS in each gene.

Ninth example, FGD4 is a gene that seemed to be involved in the regulation of the actin in the cytoskeleton and cell shape and also have various roles in proliferation, differentiation, transcriptional regulation and development.^[@DSP022C36]^ The known TSS of FGD4 was highly expressed in the nervous system tissues such as brain, spinal cord and testis. However, the TSS we identified in the FLJ55905 cDNA, which was located downstream from the known TSS of FGD4, was highly expressed in the immune system tissues such as bone marrow and spleen (Fig. [3](#DSP022F3){ref-type="fig"}E). Tenth example, C6orf32 is a gene of unknown function whose expression level increased during the myoblast differentiation of the embryo.^[@DSP022C37]^ FLJ56038 and FLJ56137 cDNAs exhibited different ORF regions as a result of FEV and were splicing variants of the known C6orf32 cDNA. The known TSS of C6orf32 was expressed at equal levels in various tissues. However, the TSSs we found in FLJ56038 and FLJ56137 cDNAs were located upstream of the known TSS of C6orf32, and both of these newly identified TSSs were highly expressed in the immune system tissues such as bone marrow, spleen and thymus (Fig. [3](#DSP022F3){ref-type="fig"}F). Eleventh example, PTPN4 is a gene belonging to the PTP (tyrosine escape phosphoric acid enzyme) family that works as a transmitter and controls various cellular processes like cell proliferation, differentiation, mitotic cycle and oncogenesis.^[@DSP022C38]^ The known TSS of PTPN4 was highly expressed in the brain, but the TSS we identified in the FLJ53929 cDNA, which was located downstream from the known TSS of TPN4, was highly expressed in the immune system tissues such as bone marrow and spleen ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Twelfth example, BTNL8 is one of the butyrophilin-like proteins and seemed to be involved in conferring immunity.^[@DSP022C39]^ The known TSS of BTNL8 was found to be expressed at equal levels in various tissues. However, the TSS we identified in the FLJ51528 cDNA, which was located downstream from the known TSS of BTNL8, was highly expressed in the lung and thymus ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Thus, it seems that these four genes regulated their expression levels in the immune system tissues by using specific TSSs.

Thirteenth example, AKT1 is a gene involved in apoptosis and neuronal differentiation and also may have a role in schizophrenia, especially in the neurotransmission system.^[@DSP022C40]^ The TSS we identified in the FLJ53606 cDNA, which was located downstream from the known TSS of AKT, was highly expressed in the retinoic acid-induced NT2 cells ([Supplementary Table S6](http://dnaresearch.oxfordjournals.org/cgi/content/full/dsp022/DC1)). Thus, this gene uses a specific TSS during the neuronal differentiation.

Thus, among the newly identified genes we have analyzed in this study, the TSSs of a number of these genes revealed specific expression patterns. These results suggest that a single gene could use alternative TSS for tissue-specific transcription. We also found a close relationship between the predicted function of a gene and its tissue-specific expression. Thus, our results suggest a strong correlation between the mRNA diversity and function of a gene.

3.6.. Construction and use of the FLJ Human cDNA Database {#s3f}
---------------------------------------------------------

We constructed the FLJ Human cDNA Database ver. 3.0 (<http://flj.lifesciencedb.jp>) based on the results of our analysis of variable protein-coding transcripts produced from a gene by AS. A detailed description of our DB is available at the DB website. The DB graphically displays mapping of all the full-length cDNAs in the human genome and their ORF regions and thus provides a lot of useful information on the mRNA diversity. Moreover, the DB not only contain sequence information on full-length human cDNAs but also contain sequence information on a huge number of human ESTs generated using the oligo-capping method, allowing us to obtain useful information on ESTs mapped on the same genome locus. Because the average length of our EST sequences was ∼500 bases, the diversity of mRNAs produced as a result of AS could be efficiently analyzed by using this information. Because we were able to accurately identify TSSs using our 5′-EST data, we believe that they could be used to understand the relationship between the variable utilization of TSSs and biological functions of genes. Moreover, one could analyze the expression profiles of the transcriptional region of genes using the data from our high accuracy 5′-EST sequences, although in some cases the results might be different from those obtained using the 3′-EST data.

Despite these useful features, our database specializes on 5′-end sequences, and therefore these data are not suitable for predicting AS in the C-terminal end. Then, a lot of AS-related information still remain to be extracted from our 1.4 million cDNA resources as all of them were not sequenced to completion. Because our cDNA resources are mostly full-length cDNAs including the TSS and the polyA site, complete sequencing of these cDNA clones will add to our understanding of the mRNA diversity. In addition, every full-length sequenced FLJ cDNAs is available from the National Institute of Technology and Evaluation (<http://www.nite.go.jp/>). We will continue to add new information on our resources to our database, and these resources will be very useful in the analysis of gene functions.

Because our interest was on the mRNAs with ORF regions different from those of already known mRNAs, we stopped sequencing the cDNA once we found that the predicted ORF region of the transcript was not different from the known mRNA (for instance, where the alternative TSS only existed in the 5′-untranslated region). We, however, found that there is a tissue specificity in the expression patterns of these genes where the variation in TSS existed in the 5′-untranslated region (results not shown). Collectively, these results suggest that depending on the situation and environment, the transcription machinery utilizes alternative TSS to regulate the expression of a transcript, even when the translated protein is same. These results are also included in our DB. We also did not complete sequencing the clones for which we were unable to predict the ORF regions of their mRNAs. However, we have also included these clones in the DB with the belief that one could obtain some new and useful information by analyzing these clones.

We discovered a lot of genes had mRNA diversity due to, for example, FEVs. We also found a lot of tissue-specific splicing patterns. Especially, in the case of FEVs that we analyzed, genes used different regions of the genome loci as the first exon, which seemed to be dependent on the tissue and its condition. We also discovered genes, the TSSs of which were located further away on the same genome locus of the gene. In these cases, there exists a high possibility that their transcription is controlled by individual transcription factors. As the mechanisms for controlling the transcription are closely related to the function, by understanding these mechanisms one could be able to artificially control the expression of an appropriate transcript in the future.

In this study, we have identified multiple transcripts producing genes, and we believe that each one of these genes is transcribed into an appropriate transcript according to the need and circumstance. Now, it will be important to know whether there is any correlation between the expression of one of the transcripts produced by a gene and a disease. For example, in the case of transcripts containing FEVs, which we analyzed in detail, only the first exon regions were different from the other previously characterized transcripts. Since the first exon regions of these transcripts are unique, it is possible to distinguish them easily from the other transcripts. It may be possible to control the expression of a specific mRNA from a group of mRNAs transcribed from a gene by targeting the first exon. As we accumulate more information on mRNA diversity of genes using approaches similar to what we have described in this study, we might be able to identify candidate genes as novel targets for the development of drugs with lower side effects.

Supplementary data {#s4}
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